Beom-Jun Kim

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer”.

Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Cancer Discovery(2022)10.1158/2159-8290.cd-22-0200

N/A

2.5DataRank · unranked

140 citations

Eric J. Jaehnig, Karsten Krug, Jonathan T. Lei, Erik J. Bergstrom, Beom-Jun Kim +34 more

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer

Cancer Research(2023)10.1158/0008-5472.can-22-3484

N/A

0.601DataRank · unranked

12 citations

Beom-Jun Kim, Meenakshi Anurag, Jonathan T. Lei, Meggie N. Young, Matthew V. Holt +11 more

PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0564

N/A

0.470DataRank · unranked

22 citations

Beom-Jun Kim, Aparna Mitra, Craig T. Vollert, Jonathan T. Lei, Diana Fandino +18 more

Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted Treatment

Cancer Research Communications(2023)10.1158/2767-9764.crc-23-0044

N/A

0.330DataRank · unranked

8 citations

Ze-Yi Zheng, Jonathan T. Lei, Matthew V. Holt, Anran Chen, Jianheng Peng +20 more

Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.102154

N/A

0.212DataRank · unranked

3 citations

Aranzazu Fernandez-Martinez, Tanmayi D. Vashist, Matthew V. Holt, LaTerrica Williams, Jonathan T. Lei +26 more

Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer

Cancer Discovery(2025)10.1158/2159-8290.cd-23-1173

N/A

0.208DataRank · unranked

3 citations

Shankha Satpathy, Karsten Krug, Jitendra K. Meena, Nivetha Ramesh Babu, Cheyenne Calderon +51 more

Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins

Cancer Research Communications(2023)10.1158/2767-9764.crc-22-0501

N/A

0.165DataRank · unranked

2 citations

Alexander B. Saltzman, Eric J. Jaehnig, Jonathan T. Lei, Anna Malovannaya, Matthew V. Holt +7 more

Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.102255

N/A

0.104DataRank · unranked

1 citations

Yongchao Dou, Meggie N. Young, Alexander B. Saltzman, Meenakshi Anurag, Jonathan T. Lei +20 more

Data from Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted Treatment

(2023)10.1158/2767-9764.c.6729507.v2

N/A

0DataRank · unranked

0 citations

Ze-Yi Zheng, Jonathan T. Lei, Matthew V. Holt, Anran Chen, Jianheng Peng +20 more

Data from Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins

(2023)10.1158/2767-9764.c.6752049

N/A

0DataRank · unranked

0 citations

Alexander B. Saltzman, Eric J. Jaehnig, Jonathan T. Lei, Anna Malovannaya, Matthew V. Holt +7 more